Dry Eye Disease Treatment Market: Introduction

Transparency Market Research has published a new report titled, ‘Global Dry Eye Disease Treatment Market.’ According to the report, the global dry eye disease treatment market was valued at ~US$ 5.4 Bn in 2019 and is projected to expand at a CAGR of ~4% from 2020 to 2030. The rise in incidence of dry eye disease, increase in research & developmental activities, surge in awareness, and growth in co-morbidities & risk factors boost the expansion of the global dry eye disease treatment market.

Anti-inflammatory Drugs to Account for Leading Share of Global Market

In terms of product, the anti-inflammatory segment is anticipated to account for major share of the global dry eye disease treatment market by 2030. The segment is expected to witness strong growth from 2020 to 2030. The anti-inflammatory segment has been split into cyclosporine, corticosteroids, and others (plastoquinonyl decyl triphenylphosphonium (Mitotech), Reproxalap (Aldeyra Therapeutics), and Lifitegrast (Xiidra)). Restasis was the market leading dry eye disease drug during 2018; however, its market share is expected to contract significantly with the arrival of generics and nine new dry eye disease drugs during the forecast period. The uptake of these novel therapeutics is anticipated to be a major driver of sales. The anti-inflammatory segment’s large market share is due to increase in clinical studies, approvals, and launch of various novel products. In February 2019, ReGenTree initiated the ARISE-3 study, the phase 3 clinical trial of the new drug RGN-259 for the treatment of dry eye syndrome. In July 2019, Novartis AG completed the acquisition of Xiidra. This acquisition enabled the company to strengthen its products portfolio.

Request a Sample of Dry Eye Disease Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S...

Artificial Tears Product to Account for Significant Market Share

Based on product, the artificial tears segment held major share of the global dry eye disease treatment market in 2019. However, the anti-inflammatory drugs segment is projected to capture the largest share of the global market by 2030. High sensitivity of topical corticosteroids, cyclosporine, and liftegrast eye drops is anticipated to contribute to the leading share of the segment. The penetration of liftegrast eye drops in Europe, Asia Pacific, Latin America, and MEA is expected to propel the segment. In the U.S., anti-inflammatory topical medications Restasis and Xiidra are the only two approved therapeutics available for the treatment of dry eye disease. In France, Germany, Italy, and the U.K., the first prescription drug for dry eye disease, the anti-inflammatory Ikervis, was only launched in 2015.

Enquiry before Buying Dry Eye Disease Treatment Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=E...

Dry Eye Disease Treatment Market: Prominent Regions

North America held the largest share of the global dry eye disease treatment market in 2019. The market in the region is projected to grow at a rapid pace during the forecast period, driven by presence of key players, technological advancements, and a highly structured healthcare industry. Increase in clinical trials, product launches, and approvals, and rise in investment by key players are anticipated to propel the dry eye disease treatment market in North America. The U.S. is expected to dominate the dry eye disease treatment market in the region during the forecast period, owing to early adoption of new technologies. The country is likely to be the most attractive market for dry eye disease treatment products, with high attractiveness index. Well-equipped hospitals, technological advancements, rise in research & development on dry eye disease for novel treatment and appropriate cure, and surge in demand for novel products & treatments are projected to augment the dry eye disease treatment market in the U.S.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B...

Dry Eye Disease Treatment Market: Key Players

Key players focus on strengthening their positions in the global dry eye disease treatment market. Companies are collaborating with other companies, conducting research studies, participating in mergers & acquisitions, and increasing product approvals and launches to secure and strengthen their positions in the global dry eye disease treatment market. In May 2020, Wize Pharma, Inc. announced the phase IV clinical trial of its prescription eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. Harbour BioMed announced completion of phase 2 study of HBM9036 in China in adult patients with moderate-to-severe dry eye disease (DED). Seciera and NOV03 & CyclASol are in clinical trial phase 3 conducted by Sun Pharmaceutical Industries Ltd. and Bausch Health Companies, Inc. (Novaliq), respectively.

Request for Analysis of COVID19 Impact on Dry Eye Disease Treatment Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=c...

Major players operating in the global dry eye disease treatment market include Novartis AG, Allergan, Bausch Health Companies, Inc., Santen Pharmaceutical Co., Ltd., OASIS Medical, Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., and RegeneRx (ReGenTree, LLC).

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/increasing-adoption-of-tar...

https://www.prnewswire.com/news-releases/initiatives-undertaken-by-...

https://www.prnewswire.co.uk/news-releases/growing-popularity-of-po...

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]

Website: https://www.transparencymarketresearch.com/